Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Firm | Analyst |
---|---|
Cantor Fitzgerald | Josh Schimmer |
Citi | Samantha Semenkow |
Cowen | Phil Nadeau Ph.D., Marc Frahm Ph.D. |
Evercore ISI | Gavin Clark-Gartner |
Guggenheim | Yatin Suneja |
H.C. Wainwright | Douglas Tsao |
Jefferies | Kelly Shi |
Morgan Stanley | Michael E. Ulz |
Stifel | Benjamin Burnett |
UBS | Trung Huynh |
Wells Fargo | Derek Archila |
William Blair | Sami Corwin, Ph.D. |
Cabaletta Bio, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Cabaletta Bio, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Cabaletta Bio, Inc. or its management. Cabaletta Bio, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.